ライフサイエンスコーパス: systolic blood pressure

1 ly included patients with sufficient data on systolic blood pressure.

2 nt for Mayo stage, nerve involvement and low systolic blood pressure.

3 sociations with coronary atherosclerosis and systolic blood pressure.

4 which had shown individual association with systolic blood pressure.

5 pituitary-thyroid axes, as well as a rise in systolic blood pressure.

6 rtensive patients, which was correlated with systolic blood pressure.

7 intensive control versus standard control of systolic blood pressure.

8 using CHX, followed by a trend of increased systolic blood pressure.

9 ying and monitoring a reliable surrogate for systolic blood pressure.

10 high-density lipoprotein, triglycerides, and systolic blood pressure]).

11 The correlation was low for systolic blood pressure (0.39; P<0.0001).

12 mum; 95% CI, 0.6-1.0 mum per decade), higher systolic blood pressure (0.5 mum; 95% CI, 0.4-0.6 mum pe

13 (-0.04% [95% CI, -0.53% to 0.46%]; P = .88); systolic blood pressure (0.78 mm Hg [95% CI, -1.48 to 3.

14 tion index), -1.1% (-2.5 to 0.3), p = 0.097; systolic blood pressure, 0.5 mm Hg (-0.6 to 1.6), p = 0.

15 sion (OR = 1.6, 95% CI = 1.2-2.3), increased systolic blood pressure (1.2 per 20mmHg, 95% CI = 1.1-1.

16 (5.4%; 95% CI, 3.8%-7.1% per decade), higher systolic blood pressure (1.2%; 95% CI, 0.5%-1.9% per 10

17 t, was associated with a significantly lower systolic blood pressure (- 1.9 (- 2.7; - 1.1) mmHg in me

18 s (-3.9 g [95% CI, -5.5 to -2.3]), and lower systolic blood pressure (-1.1 mm Hg [95% CI, -1.7 to -0.

19 gnificant between-group mean differences for systolic blood pressure (-1.26 mm Hg [95% CI, -1.77 to -

20 of stroke onset to receive intensive (target systolic blood pressure 130-140 mm Hg within 1 h) or gui

21 ed in a factorial design to target levels of systolic blood pressure (130-149mmHg vs <130mmHg; open l

22 obin (6.7+/-1.5 to 5.8+/-0.6; P<0.0001), and systolic blood pressure (145+/-13 to 118+/-11; P<0.0001)

23 >=18 years) with acute ischaemic stroke and systolic blood pressure 150 mm Hg or more, who were scre

24 re (hazard ratio=0.79 [95% CI: 0.68-0.92] at systolic blood pressure 160 vs 110 mm Hg) but not for di

25 exercise, the structural group had a higher systolic blood pressure (188+/-25 mmHg) than did those w

26 tricular mass (4.6 g [95% CI, 1.1-8.1]), and systolic blood pressure (2.3 mm Hg [95% CI, 0.93-3.6]) 6

27 land use had 1.5% (95% CI: 0.1, 2.9) higher systolic blood pressure, 2.4% (95% CI: 0.6, 4.3) higher

28 c disadvantage, 45%), body mass index (40%), systolic blood pressure (29%), insulin (20%), physical a

29 ent from the rates among those with elevated systolic blood pressure (3.78 [95% CI, 2.76-4.81]), high

30 both 15%; 4-square step test, 2% to 7%), or systolic blood pressure (-3.2 to -4.1 mm Hg).

31 ameter, and left ventricular mass and higher systolic blood pressure 6 and 9 years after pregnancy co

32 on was 29 mm Hg (SD 22), and subsequent mean systolic blood pressure achieved was 147 mm Hg (15) and

33 s significant lowering of overall ambulatory systolic blood pressure (adjusted difference -6.8mmHg, 9

34 e-type plasminogen activator) was related to systolic blood pressure; ADM (adrenomedullin) was relate

35 terval: 1.13, 1.37) per 10-mm Hg increase in systolic blood pressure among men aged <=67 years with d

36 % CI, -8.6 to -4.2; 6 studies; I2 = 51%) for systolic blood pressure and -4.0 mm Hg (95% CI, -5.6 to

37 d pressure control (defined as 120-150 mm Hg systolic blood pressure and 70-100 mm Hg diastolic blood

38 Systolic blood pressure and a diagnosis of DR were assoc

39 modeling on the association between lifetime systolic blood pressure and cognitive function in a comm

40 wide selection for traits, including height, systolic blood pressure and college education, and that

41 hm in the setting of the association between systolic blood pressure and death in older adults.

42 we created polygenic risk scores of DBP and systolic blood pressure and generated linear Mendelian r

43 amined the association between post-donation systolic blood pressure and graft failure.

44 xamined the association between postdonation systolic blood pressure and graft failure.

45 ten obese than men were, had slightly higher systolic blood pressure and heart rate, and were less li

46 -based strategy led to greater reductions in systolic blood pressure and LDL cholesterol level than w

47 y outcomes were the changes from baseline in systolic blood pressure and low-density lipoprotein (LDL

48 ract surgery, PEX was associated with higher systolic blood pressure and more frequent ECG abnormalit

49 ressure; ADM (adrenomedullin) was related to systolic blood pressure and pulse pressure; IL (interleu

50 conomic deprivation), clinical measurements (systolic blood pressure and ratio of total-high-density

51 alysis to understand the indirect effects of systolic blood pressure and serum aldosterone on the rel

52 The association between systolic blood pressure and structural progression was c

53 ndpoint was baseline-adjusted change in 24-h systolic blood pressure and the secondary efficacy endpo

54 The EN-PESA model uses age, systolic blood pressure, and 10 commonly used blood/urin

55 95% CI -14.94 to -7.97) greater reduction in systolic blood pressure, and a 0.41 mmol/L (95% CI -0.60

56 filtration rate, diabetes mellitus, elevated systolic blood pressure, and angina.

57 terial stiffness is associated with elevated systolic blood pressure, and ASI is predictive of cardio

58 and higher eosinophil count, pulse pressure, systolic blood pressure, and carotid artery procedures,

59 ty lipoprotein cholesterol concentration and systolic blood pressure, and consumption of cheese was i

60 (N-terminal Pro-B-type natriuretic peptide), systolic blood pressure, and diastolic blood pressure co

61 Beat-to-beat heart period, systolic blood pressure, and electromyography impulses w

62 ious risks to fall below dietary risks, high systolic blood pressure, and fasting plasma glucose in r

63 ng, rectal examination findings, heart rate, systolic blood pressure, and haemoglobin concentration s

64 ptimal cut point levels for glycohemoglobin, systolic blood pressure, and low-density lipoprotein cho

65 Lower levels for glycohemoglobin, systolic blood pressure, and low-density lipoprotein cho

66 albuminuria, duration of diabetes mellitus, systolic blood pressure, and low-density lipoprotein cho

67 albuminuria, duration of diabetes mellitus, systolic blood pressure, and low-density lipoprotein cho

68 e of IGF-1 (insulin-like growth factor 1) in systolic blood pressure, and the strong causal associati

69 magnitude of reduction in 1 h, mean achieved systolic blood pressure, and variability in systolic blo

70 pathways was assessed on plasma biomarkers, systolic blood pressure, aneurysm diameter, and time to

71 The reduction in 24-h ambulatory systolic blood pressure (ASBP) was significantly greater

72 The primary outcome was reduction in systolic blood pressure at 24 months.

73 systolic blood pressure at 6 months with RDN.

74 eviation (approximately 21 mmHg) increase in systolic blood pressure at baseline was associated with

75 e corresponding targets that associated with systolic blood pressure at genome-wide significance.

76 CI: 0.08, 0.76; beta: 0.03; P = .02), higher systolic blood pressure (B: 0.01; 95% CI: 0.01, 0.02; be

77 It was also associated with elevated systolic blood pressure (B=-18.0 mm Hg per L.min(-1).m(-

78 diabetes duration, most recent AER, baseline systolic blood pressure, baseline smoking, and updated m

79 iabetes, higher mean pulse rate, higher mean systolic blood pressure, beta-blocker use, estimated glo

80 systolic blood pressure, and variability in systolic blood pressure between 1 h and 24 h-and the pri

81 int was the change in the 24-hour ambulatory systolic blood pressure between baseline and 6 months.

82 adjustment for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, estimated

83 troke, atrial fibrillation, type 2 diabetes, systolic blood pressure, body mass index, and waist-to-h

84 ferences in temporal trends in the levels of systolic blood pressure, body mass index, smoking status

85 mmHg greater reduction in daytime ambulatory systolic blood pressure (BP) at 2 months by endovascular

86 It remains unclear whether systolic blood pressure (BP) influences prescription of

87 0, -0.15, P value = 4.69 x 10-10), automated systolic blood pressure (BP) measurement (beta 0.11, 95%

88 The effects of 2 levels of 24-hour average systolic blood pressure (BP) on mobility, white matter d

89 The marked reduction in systolic blood pressure (BP) seen at 6 months warranted

90 ed the associations of CD with hypertension, systolic blood pressure (BP), and diastolic BP and teste

91 e assessed the new/incident or worsened HTN (systolic blood pressure [BP] cutoff, 130 mm Hg).

92 ly mediates the association between lifespan systolic blood pressure burden and adult cognition in in

93 ss index on the association between lifetime systolic blood pressure burden and cognitive function.

94 of 18.8% of the association between lifetime systolic blood pressure burden and midlife cognitive fun

95 nce based on GRADE criteria was moderate for systolic blood pressure, but low for diastolic blood pre

96 BFM prevented the increase in systolic blood pressure, cardiac weight, and renal damag

97 risk, management targeting an individualized systolic blood pressure, compared with standard manageme

98 ngth of associations between key measures of systolic blood pressure control and safety and efficacy

99 h usual care, was noninferior with regard to systolic blood pressure control at 12 weeks.

100 n is possible without significant changes in systolic blood pressure control or adverse events during

101 or cognitive ability in youth), BMI, height, systolic blood pressure, coronary artery disease, and ty

102 blood pressure data, and we imputed missing systolic blood pressure data in 23 (1%) of the remaining

103 excluded 20 patients with insufficient or no systolic blood pressure data, and we imputed missing sys

104 The mean systolic blood pressure decreased by 9 mm Hg in the poly

105 Over 3 months, systolic blood pressure decreased, and estimated glomeru

106 When applied to body mass index, systolic blood pressure, diastolic blood pressure, and p

107 r, race, hemoglobin A1C level, hypertension, systolic blood pressure, diastolic blood pressure, and s

108 to baseline covariates: age, height, weight, systolic blood pressure, diastolic blood pressure, curre

109 r age, sex, height, weight, current smoking, systolic blood pressure, diastolic blood pressure, hyper

110 Ventilation, arterial pressure [systolic blood pressure, diastolic blood pressure, mean

111 n with CVD risk factors (p < 0.05) including systolic blood pressure, diastolic blood pressure, mean

112 N=4147) and combined with genetic effects on systolic blood pressure, diastolic blood pressure, mean

113 lipoprotein level, history of hypertension, systolic blood pressure, diastolic blood pressure, tobac

114 Intensive treatment to lower systolic blood pressure did not result in a clinically r

115 factors of NCDs (tobacco, alcohol use, high systolic blood pressure, dietary risks, high fasting pla

116 similarly strong positive associations with systolic blood pressure (each p<0.0001).

117 Although systolic blood-pressure elevation had a greater effect o

118 At 24 months, the mean systolic blood pressure fell by 9.0 mm Hg in the interve

119 Overall, systolic blood pressure fell with time, from 138 +/- 15

120 with acute ischaemic stroke, but the target systolic blood pressure for optimal outcome is uncertain

121 REBOA inflation increased systolic blood pressure from 67 (40, 83) mm Hg to 108 (9

122 Mean systolic blood pressure from baseline to 12 months decre

123 point was baseline-adjusted change in office systolic blood pressure from baseline to 3 months after

124 terrogation of DBP required us to also model systolic blood pressure, given that the 2 are strongly c

125 Participants were randomized to a systolic blood pressure goal of either less than 120 mm

126 rticipants were randomly assigned (1:1) to a systolic blood pressure goal of less than 120 mm Hg (int

127 tory adults with hypertension, treating to a systolic blood pressure goal of less than 120 mm Hg comp

128 pressure less than 65 mm Hg (p = 0.0051) or systolic blood pressure greater than 180 mm Hg (p = 0.00

129 defined by any of the following: decrease in systolic blood pressure greater than or equal to 20 mm H

130 taking antihypertensive medication or having systolic blood pressure > 140 mmHg and/or diastolic pres

131 e adults with resistant hypertension (office systolic blood pressure >/=160 mm Hg despite taking at l

132 ]; P < .001) and blood pressure variability (systolic blood pressure >180 mm Hg or <120 mm Hg) (79.7

133 e calculated the prevalence of hypertension (systolic blood pressure >=140 mm Hg or diastolic blood p

134 od pressure control for severe hypertension (systolic blood pressure >=160 mm Hg or diastolic blood p

135 ria (>=150 to <500 versus <150 mg/g), higher systolic blood pressure (>=140 versus 120 to <130 mmHg),

136 sly, an inverse association was observed for systolic blood pressure (hazard ratio=0.79 [95% CI: 0.68

137 ants were adults aged 50 years or older with systolic blood pressure higher than 130 mm Hg, but witho

138 HR, systolic blood pressure, HRV and skin conductance recove

139 t daytime and night-time with less effect on systolic blood pressure in CHF rats.

140 0.014) moderated island-specific patterns of systolic blood pressure in multivariate-adjusted models.

141 nths, there was a numerically larger fall in systolic blood pressure in the everolimus arm (between-g

142 h male and female KO mice exhibited elevated systolic blood pressure, increased urinary albumin/creat

143 nsin-aldosterone system genes associate with systolic blood pressure individually in both sexes, indi

144 ilencing PVN TNFR1 prevented the increase in systolic blood pressure induced by AngII.

145 Results from the Systolic Blood Pressure Intervention Trial (SPRINT) show

146 The previously published results of the Systolic Blood Pressure Intervention Trial showed that a

147 nd 19.5% (95% CI, 18.5-20.5) met the SPRINT (Systolic Blood Pressure Intervention Trial) eligibility

148 ssification, and data from the SPRINT trial (Systolic Blood Pressure Intervention Trial) on adverse e

149 no diabetes mellitus from the SPRINT trial (Systolic Blood Pressure Intervention Trial): 4086 random

150 (MCI) in 9361 participants in the randomized Systolic Blood Pressure Intervention Trial, which compar

151 individual participant data from the SPRINT (Systolic Blood Pressure Intervention Trial; N=9361) and

152 Although postdonation systolic blood pressure is associated with graft failure

153 Although post-donation systolic blood pressure is associated with graft failure

154 cohol intake, cheese consumption and average systolic blood pressure, largely disregarding the impact

155 etic scores for the response of 6 CRFs (BMI, systolic blood pressure, LDL cholesterol, HDL cholestero

156 ose greater than 180 mg/dL (p = 0.0003), and systolic blood pressure less than 90 mm Hg (p < 0.0001).

157 emoglobin less than 8 gm/dL (p = 0.0220), or systolic blood pressure less than 90 mm Hg (p = 0.0114).

158 ither a lactate greater than 2.2 mmol/L or a systolic blood pressure less than 90 mm Hg.

159 Prevalence of uncontrolled blood pressure (systolic blood pressure level >140 mm Hg or diastolic bl

160 d risk factors at baseline and after 1 year: systolic blood pressure, low-density lipoprotein cholest

161 (87.7%) patients in the control group had a systolic blood pressure lower than 150 mm Hg at 12 weeks

162 The primary outcome was systolic blood pressure lower than 150 mm Hg at 12-week

163 reduction, were aged 80 years and older, had systolic blood pressure lower than 150 mm Hg, and were r

164 mbination of higher respiratory rate, higher systolic blood pressure, lower central temperature, alte

165 lder, had longer hemodialysis vintage, lower systolic blood pressure, lower ultrafiltration rates, hi

166 PA reduced the body weight and systolic blood pressure, lowered fasting insulin levels,

167 response syndrome criteria) and hypotension (systolic blood pressure </=90 mm Hg or mean arterial pre

168 event risk reduction from intensive (target systolic blood pressure <120 mm Hg) versus standard (tar

169 control in YOD (hemoglobin A1c level <6.2%, systolic blood pressure <120 mm Hg, low-density lipoprot

170 Glycohemoglobin <53 mmol/mol (7.0%), systolic blood pressure <140 mm Hg, and low-density lipo

171 m it was diagnosed, treated, and controlled (systolic blood pressure <140 mm Hg, diastolic blood pres

172 haemoglobin (HbA1c) <=53 mmol/mol (<=7.0%), systolic blood pressure <140mm Hg, or <130 mm Hg if high

173 0-140 mm Hg within 1 h) or guideline (target systolic blood pressure <180 mm Hg) blood pressure lower

174 e outcome did not differ between groups (new systolic blood pressure <65 mm Hg 11 [7%] in the bolus g

175 as cardiovascular collapse, defined as a new systolic blood pressure <65 mm Hg; new or increased vaso

176 Shock was defined as sustained systolic blood pressure <90 mm Hg with end-organ dysfunc

177 Key exclusion criteria included systolic blood pressure <95 mm Hg and estimated glomerul

178 atients experienced episodes of hypotension (systolic blood pressure <= 90 mm Hg) before the onset of

179 atients experienced episodes of hypotension (systolic blood pressure <=90mmHg) prior to the onset of

180 after adjusting for effects of age, sex, and systolic blood pressure (mean B = 0.0043 [0.0008 SE], 95

181 We analysed the systolic blood pressure measures as continuous variables

182 After adjustment for age, sex, systolic blood pressure, measures of adiposity, homeosta

183 ethnicity, smokers, participants with higher systolic blood pressure, more negative refractive error,

184 CI, 1.24-1.66]; P=1.6x10(-6)), as opposed to systolic blood pressure (odds ratio, 1.06 [95% CI, 0.97-

185 d the USA, hypertensive patients with office systolic blood pressure of 150 mm Hg to less than 180 mm

186 h Glasgow Coma Scale score of 12 or less and systolic blood pressure of 90 mm Hg or higher.

187 asma concentrations of natriuretic peptides, systolic blood pressure of at least 100 mm Hg, and plan

188 mild-to-moderate renal insufficiency, and a systolic blood pressure of at least 125 mm Hg, and we ra

189 Hypertension was defined as a systolic blood pressure of at least 140 mm Hg, diastolic

190 this population, we defined hypertension as systolic blood pressure of at least 140 mm Hg, or diasto

191 composite of maternal morbidity or recorded systolic blood pressure of at least 160 mm Hg with a sup

192 on confirmed by right heart catheterisation, systolic blood pressure of at least 95 mm Hg, and no sig

193 er among those who were assigned to a target systolic blood pressure of less than 120 mm Hg (intensiv

194 ceived intensive treatment, which targeted a systolic blood pressure of less than 120 mm Hg, were sim

195 ransient ischemic attack to achieve a target systolic blood pressure of less than 140 mm Hg to reduce

196 dividualized assessment, to achieve a target systolic blood pressure of less than 140 mm Hg to reduce

197 ly at or above 150 mm Hg to achieve a target systolic blood pressure of less than 150 mm Hg to reduce

198 Fourteen of those patients had a systolic blood pressure of lower than 90mmHg.

199 Systolic blood pressure of more than 185 mm Hg is a cont

200 adverse events, only hypotension (decline in systolic blood pressure of more than 20% from baseline)

201 tigated the effects of intensive lowering of systolic blood pressure on specific cognitive functions

202 dren 1 year old or older and was present for systolic blood pressure only (-17.8 mm Hg/10 breaths/min

203 lowest, but there were no associations with systolic blood pressure or with cholesterol intake.

204 There were no differences in diastolic or systolic blood pressures or event survival (return of sp

205 .5), was 30% higher per 10 mm Hg increase in systolic blood pressure (OR = 1.3, 95% CI 1.1-1.5), and

206 R: 2.18; 95% CI: 1.58, 3.02), new-onset high systolic blood pressure (OR: 1.34; 95% CI: 1.05, 1.70),

207 (DBP; ORSD: 1.28, 95% CI 1.11-1.47), but not systolic blood pressure (ORSD: 0.98, 95% CI 0.84-1.14),

208 Mean systolic blood pressure over 24 h was 144.3 mm Hg (SD 10

209 HTx recipients, we observed a modest fall in systolic blood pressure over the first 1 to 3 years afte

210 n the final model included respiratory rate, systolic blood pressure, oxygenation, retractions, capil

211 associated with older age (P < 0.01), higher systolic blood pressure (P < 0.001), and white race (P =

212 aft failure was associated with postdonation systolic blood pressure (per 10 mm Hg, aHR 1.05, 95% CI

213 ft failure was associated with post-donation systolic blood pressure (per 10 mmHg, aHR 1.05, 95% CI 1

214 atment in adults aged 60 years or older with systolic blood pressure persistently at or above 150 mm

215 m Hg [-10.92 to -2.44 mm Hg]; p = 0.003) and systolic blood pressure (point estimate, -12.36 mm Hg [-

216 A high systolic blood pressure PRS was trans-ethnically associa

217 een serum posaconazole levels and changes in systolic blood pressure (r = .37, P = .01), a negative c

218 een serum posaconazole levels and changes in systolic blood pressure (r =.37, P=0.01), a negative cor

219 ous renal replacement therapy, hypertension (systolic blood pressure ranging from 140 to 190 mm Hg),

220 Overall, the mean magnitude of early systolic blood pressure reduction was 29 mm Hg (SD 22),

221 nd novel associations of ethnicity, smoking, systolic blood pressure, refraction, IOP(cc) and corneal

222 Non-blood biomarkers were systolic blood pressure, resting heart rate and body mas

223 history of cardiovascular disease and normal systolic blood pressure (SBP < 130 mmHg).

224 Guidelines recommend targeting systolic blood pressure (SBP) <130 mm Hg in heart failur

225 27.0, SD 4.8; controls 27.3, SD 5.6, Kg/m2), systolic blood pressure (SBP) (cases 129.0, SD 14.3; con

226 6.9% = 1.33, OR7-7.9% = 1.86, OR8%+ = 3.22), systolic blood pressure (SBP) (ORper 10mmHg+ = 1.19), an

227 e aimed to test the hypothesis that elevated systolic blood pressure (SBP) across its usual spectrum

228 Elevated systolic blood pressure (SBP) after successful revascula

229 and cerebrovascular disease was mediated by systolic blood pressure (SBP) and blood glucose levels,

230 Higher systolic blood pressure (SBP) and diastolic blood pressu

231 Systolic blood pressure (SBP) and diastolic blood pressu

232 mference (WC), waist-to-height ratio (WHtR), systolic blood pressure (SBP) and diastolic blood pressu

233 Across all participants, systolic blood pressure (SBP) and fasting blood glucose

234 showed low levels of plasma H(2)S, elevated systolic blood pressure (SBP) and renal dysfunction.

235 ssure (PAD), stroke volume index (SV index), systolic blood pressure (sBP) and RR interval measuremen

236 High systolic blood pressure (SBP) causes cardiovascular dise

237 Participants were randomized to a systolic blood pressure (SBP) goal of either less than 1

238 National guidelines recommend that systolic blood pressure (SBP) in patients with heart fai

239 High systolic blood pressure (SBP) increases cardiac afterloa

240 chronic kidney disease (CKD) with intensive systolic blood pressure (SBP) lowering is unclear.

241 Patients with an office systolic blood pressure (SBP) of 150 mm Hg or greater an

242 ; and hemoglobin A1c (HbA1c) of at least 8%, systolic blood pressure (SBP) of at least 140 mm Hg, or

243 A drop >= 20 mm Hg in systolic blood pressure (SBP) or >= 10 in diastolic bloo

244 An individual systolic blood pressure (SBP) reference value was define

245 Absolute variation in systolic blood pressure (SBP) was assessed as the absolu

246 tion of a history of hypertension and office systolic blood pressure (SBP) with major adverse cardiov

247 ty lipoprotein cholesterol (LDL-C) and lower systolic blood pressure (SBP) with the risk of cardiovas

248 The causal relationship between systolic blood pressure (SBP), calf electromyography (EM

249 fiable CHD risk factors-specifically lipids, systolic blood pressure (SBP), diabetes mellitus, and sm

250 The systolic blood pressure (SBP), diastolic blood pressure

251 would increase NO bioavailability to reduce systolic blood pressure (SBP), improve vascular function

252 ith changes in eGFR, serum creatinine (SCr), systolic blood pressure (SBP), renal hypoxia, and renal

253 ion of FR167653, p38 MAPK inhibitor, reduced systolic blood pressure (SBP), urinary albumin excretion

254 dition to age, gender, total-cholesterol and systolic blood pressure (SBP).

255 erial afterload that is out of proportion to systolic blood pressure (SBP).

256 lipoprotein cholesterol, goal <70 mg/dL) or systolic blood pressure (SBP, goal <140 mm Hg) at 1 year

257 AHM classes, within strata of baseline high (systolic blood pressure [SBP] >=140 mm Hg or diastolic b

258 ses indicate that achieving early and stable systolic blood pressure seems to be safe and associated

259 tients treated with ruxolitinib had a higher systolic blood pressure, serum AST, and ALT at 72 weeks,

260 systolic blood pressure showed a modest but statisticall

261 al (SPRINT) showed that intensive control of systolic blood pressure significantly reduced the occurr

262 Trends in systolic blood pressure, smoking status, high-density li

263 n entered by importance as VLDL cholesterol, systolic blood pressure, smoking, and IDL + LDL choleste

264 ree leading causes of YLDs in 2017, and high systolic blood pressure, smoking, high-sodium diet, and

265 h interleukin-6 (Spearman r=0.33, P<0.0001), systolic blood pressure (Spearman r=0.28, P<0.0001), bod

266 ssociations between three post-randomisation systolic blood pressure summary measures-magnitude of re

267 Choline was associated with higher systolic blood pressure, TGs, lipopolysaccharide-binding

268 s perindopril had a lower 24-hour ambulatory systolic blood pressure than those receiving perindopril

269 poor neighborhoods was associated with lower systolic blood pressure than was consistent residence in

270 edible interval -6.2 to -1.6) and for office systolic blood pressure the difference was -6.5 mm Hg (-

271 ped, extrapolating trial findings of reduced systolic blood pressure to 10-year health-care costs, ca

272 sterol, low-density lipoprotein cholesterol, systolic blood pressure, total cholesterol, triglyceride

273 y resemble participants of the SPRINT trial (Systolic Blood Pressure Trial).

274 f the following risk factors: high levels of systolic blood pressure, triglycerides, or glucose (all

275 severity indices: doppler mean COA gradient, systolic blood pressure, upper-to-lower-extremity SBP gr

276 BMF-Tg mice exhibited higher systolic blood pressure, urinary albumin/creatinine rati

277 t difference between the two groups for 24-h systolic blood pressure was -3.9 mm Hg (Bayesian 95% cre

278 f the participants was 20 kg/m2 and the mean systolic blood pressure was 115 mm Hg.

279 hieved was 147 mm Hg (15) and variability in systolic blood pressure was 14 mm Hg (8).

280 itional antihypertensive medication, and the systolic blood pressure was 14.8 mm Hg (95% confidence i

281 At baseline, the mean systolic blood pressure was 146.7 mm Hg in the intervent

282 Mean change in systolic blood pressure was 3.4 mm Hg (95% CI, 1.1 to 5.

283 ow-density lipoprotein cholesterol and lower systolic blood pressure was associated with lower cardio

284 Higher mean systolic blood pressure was associated with significantl

285 Conversely, higher systolic blood pressure was associated with WMH in periv

286 Notably, higher systolic blood pressure was associated with worse execut

287 of lorcaserin on weight, hemoglobin A1c, and systolic blood pressure was consistent regardless of bas

288 Achieved systolic blood pressure was continuously associated with

289 Systolic blood pressure was decreased through task shari

290 wer by approximately 19 mg per deciliter and systolic blood pressure was lower by approximately 5.8 m

291 The fall in systolic blood pressure was more pronounced in patients

292 Reduced systolic blood pressure was observed with IF (-4.9 mm Hg

293 After 6 mmol of KNO3, systolic blood pressure was reduced by a maximum of 17.9

294 pared to sham controls, at one week post-SAC systolic blood pressure was significantly elevated and l

295 Systolic blood pressure was the most accurate vital sign

296 ogression (all p <= 0.007); hypertension and systolic blood pressure were not.

297 c peptide), HbA1C (glycated hemoglobin), and systolic blood pressure were observed in all 3 groups.

298 ssociation between flavan-3-ol biomarker and systolic blood pressure when compared to normotensive pa

299 lesterol and for red and processed meat with systolic blood pressure, which could mediate such effect

300 atic) intracerebral haemorrhage and elevated systolic blood pressure, without a clear indication or c